Telemedicine for ALS Partnership Aims to Bridge the Gap in Care Delivery

Partnership with leading US-based ALS patient advocacy group furthers myTomorrows’ mission of ensuring that patients confronting life-threatening diseases are aware of all possible treatment options

ALS Association's Top Priorities Transformed into New Laws for Hoosiers Living with ALS

We are saddened by today’s news about Relyvrio and our hearts go out to everyone in the ALS community.

On behalf of everyone living with ALS and their families, the ALS Association sent a letter this week to members of the House and Senate demonstrating our support for the passing of the ALS Better Care Act which will increase access to multidisciplinary care clinics for people living with ALS. 

$58 Million Donation Will Advance Promising ALS Research and ALS Patient Access to Care

Legislation Marks a Milestone in Ensuring Equal Access to Health Care for Individuals with Disabilities

Shoppers at Participating Stores Can Round Up for ALS – Every Cent Counts in the Fight Against ALS

The Centers for Medicare and Medicaid Services final rule prevents health insurers from using delay tactics to deny care.

Federal Government Drops Appeal Challenging D.C. Court's Decision to Make All Copays Count.

The ALS Association, the largest ALS organization in the world, and NuvoAir, the leading value-based specialty care provider for heart and lung conditions, announced their partnership to support virtual pulmonary care for people living with ALS and their caregivers.

On behalf of everyone living with ALS and their families, the ALS Association sent a letter to CVS Caremark asking company to reconsider its current policy regarding coverage of Relyvrio.

Federal Appeal Challenges D.C. Court's Directive on Copay Assistance Inclusion in Deductibles

The ALS Association is deeply concerned and disappointed about the delay in FY24 government funding. ALS research needs to be funded and increased—NOW. People living with ALS cannot wait. We call upon policymakers to prioritize ALS research and swiftly appropriate the necessary funds to support innovative research initiatives, clinical trials and the development of potential treatments.

The U.S. District Court for the District of Columbia struck down a 2021 federal rule on Monday that allowed health insurers to not count drug manufacturer copay assistance towards a beneficiary’s out-of-pocket costs. The ALS Association is part of a coalition of patient advocacy organizations supporting the effort to end “copay accumulator” policies.

On the heel of the FDA's decision on NurOwn, we are sharing our thoughts with the ALS community in our statement.

The possibility of a government shutdown could have far-reaching and disastrous consequences for people living with ALS and those who depend on government-funded programs and support systems. A shutdown will disrupt the vital services and resources that many individuals with ALS and their families rely on daily.

With the Food and Drug Administration’s approval of the first gene-targeted therapy for ALS – and at least nine more in clinical development – genetic counseling and testing has become increasingly important. However, genetic counseling and testing is still not routinely offered to people with ALS in the United States.

Leveraging more than $3 million in support from The ALS Association, researchers from UMass Chan Medical School, the National Institutes of Health and Emory University have developed a cloud-based central repository of genetic data related to ALS and frontotemporal dementia (FTD). ALS Compute compiles data from multiple large-scale initiatives into one easily accessible dataset that is far more powerful than any single dataset alone.   

The ALS Association and ALS Finding a Cure® have awarded seven new grants worth a total of $2 million over the next three years to support the development of early diagnostics for ALS.